That's why the competitor is down 22% already
July 31, 2015
Synergy Pharmaceuticals (SGYP) Stock Is Headed For Massive Gains
I’ve got overwhelmingly bullish expectations for Synergy Pharmaceuticals stock. The reality is that the plecanatide study went incredibly well; and following the strong phase 3b results, the company is planning on an NDA submission in the near future. In the world of biotech, these types of things tend to be catalysts that lead to strong growth in the stock the events are represented by. It would also make sense for an acquisition to take place. So, we’ll want to keep an eye out for any developments there as a buyout offer would likely send Synergy Pharmaceuticals soaring in the market. Nonetheless, whether or not a buyout happens, I’m expecting to see strong growth in the long run. Synergy is likely to represent incredibly profitable buying opportunities.
Grabbed some, $5's for statistically significant endpoint with 42% reduction in cancer progression or death is a buy opportunity
game over for shorts
good buy opportunity Holding this baby..